粉尘子成分分析:识别关键的过敏原成分,以有效的免疫治疗过敏性鼻炎
Jingyu Huang1, Rong Xiang1, Lu Tan1
1Department of Rhinology and Allergy, Otolaryngology-Head and Neck Surgery Center, Renmin Hospital of Wuhan University, Wuhan, China.
International immunopharmacology
|November 5, 2023
概括
在接受皮下免疫疗法 (SCIT) 的过敏性鼻炎患者中,室内灰尘虫 (HDM) 敏感性配置不同. 特定的IgE水平和细胞因子变化与SCIT疗效相关,有助于患者选择和治疗监测.
科学领域:
- 免疫学 免疫学 免疫学
- 过敏学 过敏学
- 生物标志物 生物标志物
背景情况:
- 家庭灰尘虫 (HDM) 敏感性在过敏性鼻炎中很常见.
- 皮下免疫疗法 (SCIT) 是过敏性鼻炎的治疗选择.
- 了解敏感化概况可以优化SCIT的有效性.
研究的目的:
- 在接受SCIT的过敏性鼻炎患者中,确定对HDM成分的敏感性频率.
- 评估SCIT有效性和针对HDM过敏原的特定IgE (sIgE) 水平之间的关系.
- 为了确定监测SCIT治疗结果的潜在生物标志物.
主要方法:
- 收集了38名过敏性鼻炎患者的血清样本和临床数据,这些患者接受了HDM-SCIT.
- 使用酶免疫测试测量了特定的HDM成分 (Derf,Derp1,Derp2,Derp10,Derp23) 的sIgE水平.
- 通过ELISA分析了细胞因子水平 (IL-2,IL-4,IL-6) 和EOS%,并与临床疗效相关 (治疗指数>50%).
主要成果:
- 对于主要的HDM过敏原 (Der p,Der f,Der p1,Der p2) 观察到高敏感率.
- 响应SCIT的患者对HDM组件的IgE水平基线较高,特别是Der p 1.
- 有效的SCIT与降低的sIgE水平以及降低的IL-2,IL-4,IL-6和EOS%相关,而无效的治疗显示出相反的趋势.
结论:
- 在HDM-SCIT中,分子敏感性概况是多样化的,并且与治疗成功有关.
- 分子诊断可以帮助选择适合HDM-SCIT的候选人,改善临床结果.
- 血清细胞因子水平 (IL-2,IL-4,IL-6) 和EOS%显示为监测HDM-SCIT疗效的生物标志物具有前途.
相关概念视频
Allergic Reactions
27.6K
Overview
27.6K
Asthma: Pathogenesis and Management
420
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
420
Asthma-I: Introduction
2.6K
Asthma is a chronic respiratory ailment that requires careful management due to its varying symptoms and influencing factors. It is characterized by airway inflammation, bronchial hyperresponsiveness, and reversible airflow obstruction, leading to symptoms like wheezing, shortness of breath, chest tightness, and coughing. The symptom frequency and intensity may vary considerably over time. It is also linked to immune system responses to allergens and irritants, highlighting the complex...
2.6K
Asthma-II: Pathophysiology and Classification
2.7K
Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
2.7K
Antibody Structure
60.2K
Overview
Antibodies, also known as immunoglobulins (Ig), are essential players of the adaptive immune system. These antigen-binding proteins are produced by B cells and make up 20 percent of the total blood plasma by weight. In mammals, antibodies fall into five different classes, which each elicits a different biological response upon antigen binding.
The Y-Shaped Structure of Antibodies Consists of Four Polypeptide Chains
Antibodies consist of four polypeptide chains: two identical heavy...
Antibodies, also known as immunoglobulins (Ig), are essential players of the adaptive immune system. These antigen-binding proteins are produced by B cells and make up 20 percent of the total blood plasma by weight. In mammals, antibodies fall into five different classes, which each elicits a different biological response upon antigen binding.
The Y-Shaped Structure of Antibodies Consists of Four Polypeptide Chains
Antibodies consist of four polypeptide chains: two identical heavy...
60.2K
Drugs Used in Lower Respiratory Disorders: Overview
455
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
455


